Humana Inc.

Humana Inc.

HUMNYSE / NASDAQHealthcareLarge cap

$390.00+$10.00 (+2.6%)

Last close · Data as of Nov 20, 2026

Market cap
$42.0B
P/E
35.4x
Revenue
$129.7B
Net margin
0.9%
ROCE
7.3%

+74.7% over the last year

Humana Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-8.7%
3M
+2.4%
6M
+28.2%
1Y
+74.7%
5Y
-10.3%

52-week range

Day change +$10.00 (+2.6%) from $380 to $390 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HUM, bought on each weekday since 2021.

News & filings

What Humana filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernNet margin of 0.9% against a peer median of 18.2%.

Strengths (1)

  • Cash on the balance sheet equals 47% of the company's market value.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell.

Read moreShow less

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Sector
Healthcare
Shares outstanding
120.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$42.0B
P/E
35.4x
P/B
2.4x
EV / Sales
0.3x
P/S
0.3x
52-week high
$461.25
52-week low
$163.67

Profitability

Operating margin
1.7%
Net margin
0.9%
ROE
6.7%
ROCE
7.3%
ROA
2.4%
Asset turnover
2.65

Growth

Revenue
$129.7B
Revenue growth, 1Y
10.1%
Revenue CAGR, 3Y
11.8%
Net profit growth, 1Y
-1.6%
Free cash flow
$375.0M

Solvency

Debt / Equity
0.70
Debt / Assets
0.25
CFO / Net profit
0.78
Cash / Market cap
47.4%

Where the revenue went

Some FY2025 lines are not reported, so the ones that are appear as a table.

LineFY2025
Revenue$129.7B
Gross profit$129.7B
Pretax income$1.6B
Tax and other$367.0M
Net income$1.2B

Revenue and net profit

Revenue grew 10.1% in FY2025; net profit is the dashed line.

Humana Inc. revenue and net profit by fiscal year
Humana Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$92.9B$2.8B
FY2023$106.4B$2.5B
FY2024$117.8B$1.2B
FY2025$129.7B$1.2B

Cash flows

FY2025: $921.0M from operations, $375.0M free after investment (dashed).

Humana Inc. operating and free cash flow by fiscal year
Humana Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$4.6B$3.5B
FY2023$4.0B$3.0B
FY2024$3.0B$2.4B
FY2025$921.0M$375.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$129.7B+10.1%1Y
Net profit
$1.2B-1.6%1Y
Cash from operations
$921.0M-68.9%1Y
Free cash flow
$375.0M-84.3%1Y
Revenue CAGR, 3Y
11.8%
Net profit CAGR, 3Y
-24.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$129.7B—$1.2B$375.0M6.7%+10.1%-1.6%

Monthly returns

Month-by-month returns of HUM across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$48.9B
Liabilities$31.2B
Equity$17.7B
Paid-in capital$3.6B
Retained earnings$29.1B
Treasury stock$14.4B
Minority interest$80.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HUM highlighted.

P/E against peers

HUM trades at 35.4x earnings against a peer median of 36.2x.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Humana Inc.HUMthis company$42.0B35.4x2.4x6.7%—
Edwards Lifesciences CorporationEW$50.4B46.9x4.9x10.4%33.2x
Cardinal Health, Inc.CAH$47.2B30.3x-17.0x-56.1%16.7x
IDEXX Laboratories, Inc.IDXX$44.5B42.0x27.7x66.0%30.1x
Becton, Dickinson and CompanyBDX$41.2B24.6x1.6x6.6%12.1x
Alnylam Pharmaceuticals, Inc.ALNY$40.5B129.2x51.4x39.8%61.6x
Agilent Technologies, Inc.A$39.1B30.0x5.8x19.3%22.1x
Waters CorporationWAT$37.0B57.5x14.4x25.1%36.7x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
Peer median—36.2x7.9x22.2%26.1x

Year-to-date ROI

HUM since 1 January, against earlier years.

Historical volatility

HUM's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expenses
Other operating expensesOther Operating Expenses$15.9B
Depreciation and amortisationDepreciation And Amortization In Income Statement$698.0M
Total expensesTotal Expenses$128.1B
Pretax incomePretax Income$1.6B

Learn while you research

Academy chapters picked for Humana Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 35.4, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →